Acadia Pharmaceuticals Inc. (ACAD) said Wednesday that its Phase 3 COMPASS PWS study of carbetocin for the treatment of patients with hyperphagia or extreme hunger associated with Prader-Willi syndrome failed to meet its primary endpoint.
COMPASS PWS was a 12-week, randomized, placebo-controlled global Phase 3 trial evaluating the efficacy and safety of intranasal carbetocin in individuals aged 5 to 30 years with Prader-Willi syndrome (PWS), a rare genetic disorder. The trial found that intranasal carbetocin did not show a statistically significant improvement over placebo on the primary endpoint—the change from baseline to Week 12 on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), a caregiver-reported measure of food-seeking behaviors in individuals with PWS.
The safety and tolerability profile of intranasal carbetocin was consistent with previous trials, with a low rate of adverse events.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.